CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 62 enrolled
Drug / intervention
Methylene bluedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00784849
NCT00784849Phase 2Completed

Pilot Trial to Determine the Feasibility of a One Step Sentinel Lymph Node Biopsy Procedure Using Radiolabeled Methylene Blue (IND 70,627)

Louisiana State University Health Sciences Center in New Orleans·interventional·Posted Nov 4, 2008·Updated Jun 20, 2012

In Brief

A Phase 2 clinical trial evaluating Methylene blue for Breast Cancer. Completed, enrolled 62 participants across 2 sites.

Detailed Summary

The purpose of this study is to develope a one-step procedure to perform a biopsy of axillary lymph nodes on the same side as the breast tumor in women diagnosed with breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 4, 2008
Enrollment StartNov 1, 2004
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 17.7 years ago

Interventions

Methylene bluedrug

1 mC1